Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2004.046490v1, 2005; 10.1373/clinchem.2004.046490
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2004.046490v1
51/7/1154    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rossetti, L. C.
Right arrow Articles by De Brasi, C. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rossetti, L. C.
Right arrow Articles by De Brasi, C. D.

Received on December 7, 2004
Accepted on April 5, 2005

Hemostasis and Thrombosis

Genotyping the Hemophilia Inversion Hotspot by Use of Inverse PCR

Liliana Carmen Rossetti 1*, Claudia Pamela Radic 1, Irene Beatriz Larripa 1, Carlos Daniel De Brasi 1

1 Department of Genetics, Instituto de Investigaciones Hematológicas Mariano R. Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina

* To whom correspondence should be addressed. E-mail: rossetti{at}hematologia.anm.edu.ar.

Background: Factor VIII intron 22 inversions (Inv22) cause 40%-45% of severe cases of hemophilia A in all human populations. Currently, Inv22 can be analyzed either by Southern blotting or by rapid long-distance-PCR-based approaches. We describe an alternative method using inverse-PCR (I-PCR).

Methods: I-PCR involved 3 steps: (a) BclI restriction; (b) self-ligation of restriction fragments, providing BclI rings; and (c) standard multiplex-PCR analysis. PCR was achieved by use of a set of 3 primers that yielded a 487-bp amplicon for the nonrearranged intragenic allele and a 559-bp amplicon for the Inv22 allele. Specific primer sites were targeted by masking relevant regions for human repeats and low-complexity DNA. Inv22 I-PCR was applied to samples from 16 individuals (8 women and 8 men) representing 24 X chromosomes previously genotyped by Southern blotting. Additionally, we evaluated the sensitivity and the ability to assess eventual Inv22 carrier mosaicisms by experiments using artificial DNA mixtures (Inv22 + no-Inv22 male samples).

Results: Results for previously genotyped samples agreed with results of Southern blot analyses. As expected, cell composition of the artificial mosaic was linearly reflected by the relative intensities of Inv22 signals. I-PCR was estimated to detect Inv22-positive cells at concentrations as low as ~5%.

Conclusion: The proposed technique provides a rapid tool for Inv22 genotyping.




The following articles in journals at HighWire Press have cited this article:


Home page
NEJMHome page
K. R. Viel, A. Ameri, T. C. Abshire, R. V. Iyer, R. G. Watts, C. Lutcher, C. Channell, S. A. Cole, K. M. Fernstrom, S. Nakaya, et al.
Inhibitors of Factor VIII in Black Patients with Hemophilia
N. Engl. J. Med., April 16, 2009; 360(16): 1618 - 1627.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
L. C. Rossetti, C. P. Radic, M. Candela, R. P. Bianco, M. de Tezanos Pinto, A. Goodeve, I. B. Larripa, and C. D. De Brasi
Sixteen novel hemophilia A causative mutations in the first Argentinian series of severe molecular defects
Haematologica, June 1, 2007; 92(6): 842 - 845.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.